Edition:
United Kingdom

People: Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

3.01EUR
17 May 2019
Change (% chg)

€0.05 (+1.52%)
Prev Close
€2.96
Open
€3.00
Day's High
€3.01
Day's Low
€2.98
Volume
12,486
Avg. Vol
42,245
52-wk High
€3.38
52-wk Low
€2.57

Archinard, Philippe 

Mr. Philippe Archinard has served as Chairman of the Board of Directors, Chief Executive Officer and Member of the Management Committee at Transgene SA since June 17, 2010. Prior to that, he served as Chief Executive Officer, Member of the Board of Directors and Member of the Management Committee since December 6, 2004. He began his professional career with bioMerieux in 1985, where he held various positions in France and the United States, including Chief Executive Officer (CEO) of the American operations. Since March 2000, he had served as Chief Executive Officer of Innogenetics until his appointment as CEO of the Company. Mr. Archinard also holds other mandates, including Permanent Representative of TSGH on the Board of ABL Inc, Director of ERYtech Pharma and as well as Chairman of the bioMerieux Inc. He holds a Chemical Engineering degree and a Doctorate degree in Biochemistry, both from Universite de Lyon and has completed the PMD program at the Harvard Business School.

Basic Compensation

Total Annual Compensation, EUR 732,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 732,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --